Trials / Completed
CompletedNCT01756261
EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan
Special Drug Use Investigation of EYLEA for Quality of Life
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 757 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The objective of this survey is to evaluate effectiveness of EYLEA on Quality of Life (QOL). The QOL is evaluated by using Japanese version (v.1.4 - interviewer administered format) of National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) and compared at baseline and at the 6 and 12 months after start of EYLEA treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Patients treated with EYLEA under practical manner for AMD. |
Timeline
- Start date
- 2012-12-26
- Primary completion
- 2016-07-20
- Completion
- 2017-02-27
- First posted
- 2012-12-25
- Last updated
- 2018-06-19
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01756261. Inclusion in this directory is not an endorsement.